Copyright Reports & Markets. All rights reserved.

Global Primary Sclerosing Cholangitis Treatment Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Liver Transplantation Operation
      • 1.4.3 UDCA Drugs
      • 1.4.4 PSC Drugs
    • 1.5 Market by Application
      • 1.5.1 Global Primary Sclerosing Cholangitis Treatment Market Share by Application (2019-2025)
      • 1.5.2 Hospital
      • 1.5.3 Clinics
      • 1.5.4 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Primary Sclerosing Cholangitis Treatment Market Size
    • 2.2 Primary Sclerosing Cholangitis Treatment Growth Trends by Regions
      • 2.2.1 Primary Sclerosing Cholangitis Treatment Market Size by Regions (2019-2025)
      • 2.2.2 Primary Sclerosing Cholangitis Treatment Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Primary Sclerosing Cholangitis Treatment Market Size by by Players
      • 3.1.1 Global Primary Sclerosing Cholangitis Treatment Revenue by by Players (2014-2019)
      • 3.1.2 Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Primary Sclerosing Cholangitis Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Primary Sclerosing Cholangitis Treatment Key Players Head office and Area Served
    • 3.3 Key Players Primary Sclerosing Cholangitis Treatment Product/Solution/Service
    • 3.4 Date of Enter into Primary Sclerosing Cholangitis Treatment Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Primary Sclerosing Cholangitis Treatment Market Size by Type (2014-2019)
    • 4.2 Global Primary Sclerosing Cholangitis Treatment Market Size by Application (2014-2019)

    5 North America

    • 5.1 North America Primary Sclerosing Cholangitis Treatment Market Size (2014-2019)
    • 5.2 Primary Sclerosing Cholangitis Treatment Key Players in North America
    • 5.3 North America Primary Sclerosing Cholangitis Treatment Market Size by Type
    • 5.4 North America Primary Sclerosing Cholangitis Treatment Market Size by Application

    6 Europe

    • 6.1 Europe Primary Sclerosing Cholangitis Treatment Market Size (2014-2019)
    • 6.2 Primary Sclerosing Cholangitis Treatment Key Players in Europe
    • 6.3 Europe Primary Sclerosing Cholangitis Treatment Market Size by Type
    • 6.4 Europe Primary Sclerosing Cholangitis Treatment Market Size by Application

    7 China

    • 7.1 China Primary Sclerosing Cholangitis Treatment Market Size (2014-2019)
    • 7.2 Primary Sclerosing Cholangitis Treatment Key Players in China
    • 7.3 China Primary Sclerosing Cholangitis Treatment Market Size by Type
    • 7.4 China Primary Sclerosing Cholangitis Treatment Market Size by Application

    8 Japan

    • 8.1 Japan Primary Sclerosing Cholangitis Treatment Market Size (2014-2019)
    • 8.2 Primary Sclerosing Cholangitis Treatment Key Players in Japan
    • 8.3 Japan Primary Sclerosing Cholangitis Treatment Market Size by Type
    • 8.4 Japan Primary Sclerosing Cholangitis Treatment Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size (2014-2019)
    • 9.2 Primary Sclerosing Cholangitis Treatment Key Players in Southeast Asia
    • 9.3 Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size by Type
    • 9.4 Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size by Application

    10 India

    • 10.1 India Primary Sclerosing Cholangitis Treatment Market Size (2014-2019)
    • 10.2 Primary Sclerosing Cholangitis Treatment Key Players in India
    • 10.3 India Primary Sclerosing Cholangitis Treatment Market Size by Type
    • 10.4 India Primary Sclerosing Cholangitis Treatment Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Primary Sclerosing Cholangitis Treatment Market Size (2014-2019)
    • 11.2 Primary Sclerosing Cholangitis Treatment Key Players in Central & South America
    • 11.3 Central & South America Primary Sclerosing Cholangitis Treatment Market Size by Type
    • 11.4 Central & South America Primary Sclerosing Cholangitis Treatment Market Size by Application

    12 International Players Profiles

    • 12.1 Allergan
      • 12.1.1 Allergan Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Primary Sclerosing Cholangitis Treatment Introduction
      • 12.1.4 Allergan Revenue in Primary Sclerosing Cholangitis Treatment Business (2014-2019))
      • 12.1.5 Allergan Recent Development
    • 12.2 Glenmark
      • 12.2.1 Glenmark Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Primary Sclerosing Cholangitis Treatment Introduction
      • 12.2.4 Glenmark Revenue in Primary Sclerosing Cholangitis Treatment Business (2014-2019)
      • 12.2.5 Glenmark Recent Development
    • 12.3 Impax Laboratories
      • 12.3.1 Impax Laboratories Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Primary Sclerosing Cholangitis Treatment Introduction
      • 12.3.4 Impax Laboratories Revenue in Primary Sclerosing Cholangitis Treatment Business (2014-2019)
      • 12.3.5 Impax Laboratories Recent Development
    • 12.4 Mylan
      • 12.4.1 Mylan Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Primary Sclerosing Cholangitis Treatment Introduction
      • 12.4.4 Mylan Revenue in Primary Sclerosing Cholangitis Treatment Business (2014-2019)
      • 12.4.5 Mylan Recent Development
    • 12.5 Teva Pharmaceuticals
      • 12.5.1 Teva Pharmaceuticals Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Primary Sclerosing Cholangitis Treatment Introduction
      • 12.5.4 Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2014-2019)
      • 12.5.5 Teva Pharmaceuticals Recent Development
    • 12.6 Dr. Falk Pharma
      • 12.6.1 Dr. Falk Pharma Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Primary Sclerosing Cholangitis Treatment Introduction
      • 12.6.4 Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2014-2019)
      • 12.6.5 Dr. Falk Pharma Recent Development
    • 12.7 Daewoong Pharmaceutical
      • 12.7.1 Daewoong Pharmaceutical Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Primary Sclerosing Cholangitis Treatment Introduction
      • 12.7.4 Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis Treatment Business (2014-2019)
      • 12.7.5 Daewoong Pharmaceutical Recent Development
    • 12.8 Epic Pharma
      • 12.8.1 Epic Pharma Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Primary Sclerosing Cholangitis Treatment Introduction
      • 12.8.4 Epic Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2014-2019)
      • 12.8.5 Epic Pharma Recent Development
    • 12.9 Mitsubishi Tanabe Pharma
      • 12.9.1 Mitsubishi Tanabe Pharma Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Primary Sclerosing Cholangitis Treatment Introduction
      • 12.9.4 Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2014-2019)
      • 12.9.5 Mitsubishi Tanabe Pharma Recent Development
    • 12.10 Lannett
      • 12.10.1 Lannett Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Primary Sclerosing Cholangitis Treatment Introduction
      • 12.10.4 Lannett Revenue in Primary Sclerosing Cholangitis Treatment Business (2014-2019)
      • 12.10.5 Lannett Recent Development
    • 12.11 Bruschettini
    • 12.12 Shanghai Pharma
    • 12.13 Grindeks
    • 12.14 Acorda Therapeutics
    • 12.15 Gilead Sciences
    • 12.16 Intercept Pharmaceuticals
    • 12.17 Shire Plc
    • 12.18 NGM Biopharmaceuticals
    • 12.19 Conatus Pharmaceuticals
    • 12.20 Durect Corporation
    • 12.21 Sirnaomics
    • 12.22 Shenzhen HighTide Biopharmaceuticals

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Product (2019-2025)
    • 13.2 Market Size Forecast by Application (2019-2025)
    • 13.3 Market Size Forecast by Regions
    • 13.4 North America
    • 13.5 Europe
    • 13.6 China
    • 13.7 Japan
    • 13.8 Southeast Asia
    • 13.9 India
    • 13.10 Central & South America

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 15.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      This report focuses on the global Primary Sclerosing Cholangitis Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Primary Sclerosing Cholangitis Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      Allergan
      Glenmark
      Impax Laboratories
      Mylan
      Teva Pharmaceuticals
      Dr. Falk Pharma
      Daewoong Pharmaceutical
      Epic Pharma
      Mitsubishi Tanabe Pharma
      Lannett
      Bruschettini
      Shanghai Pharma
      Grindeks
      Acorda Therapeutics
      Gilead Sciences
      Intercept Pharmaceuticals
      Shire Plc
      NGM Biopharmaceuticals
      Conatus Pharmaceuticals
      Durect Corporation
      Sirnaomics
      Shenzhen HighTide Biopharmaceuticals

      Market segment by Type, the product can be split into
      Liver Transplantation Operation
      UDCA Drugs
      PSC Drugs

      Market segment by Application, split into
      Hospital
      Clinics
      Other

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Primary Sclerosing Cholangitis Treatment status, future forecast, growth opportunity, key market and key players.
      To present the Primary Sclerosing Cholangitis Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Primary Sclerosing Cholangitis Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
      Buy now